Lenvima
What Lenvima is used for
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Lenvima
- Active substance
- lenvatinib
- Disease area
- Thyroid Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE
- Marketing authorisation holder
- Eisai GmbH
- Authorised in the EU since
- 2015
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Lenvima used for?
Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI). Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.
What is the active substance in Lenvima?
Lenvima contains lenvatinib.
Who makes Lenvima?
The EU marketing authorisation holder is Eisai GmbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU